



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Matsui <i>et al.</i>	)	Art Unit: 1631
	)	
Application No.: 08/439,095	)	Examiner: Skibinsky A.
	)	
Filing Date: May 11, 1995	)	Confirmation No.: 8286
	)	
For: TYPE ALPHA PLATELET DERIVED	)	
GROWTH FACTOR RECEPTOR	)	

**COMMUNICATION**

MAIL STOP ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 36339

Sir:

Pursuant to the May 5, 2008 telephone interview between Examiner Anna Skibinsky and Lizette Fernandez of our office regarding the above-referenced patent application, applicants respectfully request that the following Examiner's amendments (shown in the middle of page 2, in the Detailed Action section of the Notice of Allowance mailed February 8, 2008) not be entered:


- In claim 1, line 11, after "fragments"; insert -- to each other --.
- In claim 1, line 14, replace "oligonucleotides" with --nucleotides--.
- In claim 1, line 15, after "2"; insert --,--.
- In claim 5, line 8, replace "valuesfor" with --values for--.
- In claim 5, line 3, replace "selectedspecific" with --selected specific--.

As confirmed by Examiner Skibinsky in the telephone interview, these amendments were inadvertently included in the Notice of Allowance, and do not pertain to this application.

A Credit Card Payment Form PTO-2038 in the amount of \$1470.00, representing the fee for a large entity under 37 CFR 1.18(a) in the amount of \$1440.00, and the fee for ten additional copies of patent in the amount of \$30.00, an Issue Fee Transmittal Form, Submission of Replacement Drawings (Figures 12 and 13), and Fee Address Indication Form are enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Gwendolyn D. Spratt  
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.  
Customer Number 36339  
(678) 420-9300 Phone  
(678) 420-9301 Fax

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.



Gwendolyn D. Spratt

• May 8, 2008

Date



ATTORNEY DOCKET NO. 14014.0279US  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Matsui et al.	)	Art Unit: 1631
	)	
Application No. 08/439,095	)	Examiner: Anna Skibinsky
	)	
Filing Date: May 11, 1995	)	Confirmation No. 8286
	)	
For: TYPE ALPHA PLATELET DERIVED	)	
GROWTH FACTOR RECEPTOR	)	

**SUBMISSION OF REPLACEMENT DRAWINGS**

Mail Stop Issue Fee  
Commissioner for Patents  
Alexandria, VA 22313-1450


NEEDLE & ROSENBERG, P.C.  
Customer Number 36339

Sir:

In response to the Notice to File Corrected Application Papers mailed March 18, 2008 regarding the above-referenced patent application, a copy of which is attached, submitted herewith are two (2) sheets of replacement drawings (Figures 12 and 13).

Respectfully submitted

NEEDLE & ROSENBERG, P.C.

  
Gwendolyn D. Spratt  
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.  
Customer Number 36339  
(678) 420-9300  
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Gwendolyn D. Spratt

Gwendolyn D. Spratt

May 8, 2008

Date

**IDENTIFICATION OF DRAWING DEFICIENCIES**

- ☐ There is a hole or the image thereof within the illustration. FIG(s) \_\_\_\_\_
- ☐ The character of the lines, numbers and letters is poor. FIG(s) \_\_\_\_\_
- ☐ The illustration is penetrated or traversed by a solid or broken line that is not intended to be part of the drawing, such as a dark line caused by a flaw in the copying process. FIG(s) \_\_\_\_\_
- ☐ An ink stamp or an image obscures part of the illustration. FIG(s) \_\_\_\_\_
- ☐ The drawing is marred by black smudges, obliterations, or fax/copier marks. FIG(s) \_\_\_\_\_
- ☐ Figure numbers are duplicated or missing. FIG(s). \_\_\_\_\_
- ☐ Numbers, letters, or reference characters in the drawing have been crossed out by hand or are illegibly handwritten. FIG(s) \_\_\_\_\_
- ☐ The drawing's background shows that the original drawing was made on graph paper or other paper with a pattern or decoration. FIG(s) \_\_\_\_\_
- ☐ The FIG. number label is placed in a location that causes the drawing to be read upside down. FIG(s) \_\_\_\_\_
- ☐ Data, a reference number, or part of the drawing is truncated or missing. FIG(s) \_\_\_\_\_
- ☐ The drawing is continued onto a second page (or more) without proper labeling under 37 CFR 1.84(u)(1). FIG(s) \_\_\_\_\_
- ☐ The drawing and/or the FIG. label contain(s) foreign language. FIG(s) \_\_\_\_\_
- ☐ Color drawings are present in this application but the following 37 CFR 1.84(a) requirements have not been met\*:
  - ☐ Petition filed
  - ☐ Petition fee
  - ☐ 3 sets of color drawings
  - ☐ Color drawing paragraph

\*If color drawings are not elected, then applicant **must respond** so stating. Also, references to color drawings in the specification, if any, must be amended.381.

COMMENTS: **Figs. 12 & 13 appear to be on graph paper. Please provide replacement drawings. .**




Figure 12. DNA synthesis stimulation responses to PDGF-AB (triangles) or PDGF-BB (circles) by human D32 cells reconstituted with type  $\alpha$  (upper panel) or type  $\beta$  (lower panel) PDGF receptors.

5




Figure 13. Chemotactic responses to PDGF-AB (triangles) or PDGF-BB (circles) by human D32 cells reconstituted with type  $\alpha$  (upper panel) or type  $\beta$  (lower panel) PDGF receptors.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Serial No. : 08/439,095  
Applicant: Matsui  
Filing Date : 05/11/05  
Date Mailed : 03/18/08

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

### *Notice of Allowance Mailed*

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given 2 months from the mail date of this Notice within which to correct the informalities indicated below. If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to reply will result in the application being ABANDONED. **This period for reply is NOT extendable under 37 CFR 1.136(a).**

See attachment.

**Figs. 12-13 appear to be on graph paper. Please provide replacement drawings.**

*A copy of this notice **MUST** be returned with the reply. Please address response to  
"Mail Stop Issue Fee, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450".*

**L. Fletcher** \_\_\_\_\_  
Your name  
Office of Patent Publication  
Phone: 703-308-9250, ext. 143